Concepts (260)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Parkinsonian Disorders | 9 | 2023 | 210 | 4.130 |
Why?
|
| Stroke | 20 | 2023 | 259 | 4.060 |
Why?
|
| Brain | 14 | 2023 | 1560 | 3.090 |
Why?
|
| Alzheimer Disease | 12 | 2023 | 1962 | 2.940 |
Why?
|
| Cognitive Dysfunction | 9 | 2023 | 1017 | 2.590 |
Why?
|
| Cerebrovascular Disorders | 4 | 2023 | 120 | 1.840 |
Why?
|
| Aged, 80 and over | 25 | 2023 | 4459 | 1.640 |
Why?
|
| Brain Ischemia | 5 | 2020 | 58 | 1.530 |
Why?
|
| Female | 52 | 2023 | 14273 | 1.510 |
Why?
|
| Aged | 37 | 2023 | 8501 | 1.500 |
Why?
|
| Intracranial Arteriosclerosis | 2 | 2022 | 50 | 1.480 |
Why?
|
| Male | 50 | 2023 | 13917 | 1.440 |
Why?
|
| Humans | 63 | 2023 | 25692 | 1.270 |
Why?
|
| Apolipoprotein E4 | 2 | 2020 | 244 | 1.130 |
Why?
|
| Hypertension | 8 | 2023 | 201 | 1.120 |
Why?
|
| Risk Factors | 24 | 2023 | 2224 | 1.090 |
Why?
|
| Atherosclerosis | 3 | 2023 | 55 | 1.080 |
Why?
|
| Dementia, Vascular | 2 | 2016 | 45 | 1.040 |
Why?
|
| Disease Progression | 5 | 2021 | 664 | 1.000 |
Why?
|
| Neuropsychological Tests | 5 | 2023 | 1176 | 1.000 |
Why?
|
| Incidence | 15 | 2022 | 731 | 0.990 |
Why?
|
| Arteriolosclerosis | 2 | 2023 | 72 | 0.970 |
Why?
|
| Independent Living | 4 | 2023 | 294 | 0.950 |
Why?
|
| TDP-43 Proteinopathies | 2 | 2023 | 101 | 0.940 |
Why?
|
| Cardiovascular Diseases | 10 | 2018 | 340 | 0.900 |
Why?
|
| Limbic Encephalitis | 1 | 2023 | 8 | 0.870 |
Why?
|
| Amyloid beta-Peptides | 4 | 2023 | 315 | 0.860 |
Why?
|
| tau Proteins | 3 | 2023 | 219 | 0.850 |
Why?
|
| Motor Disorders | 1 | 2023 | 24 | 0.850 |
Why?
|
| Disabled Persons | 2 | 2023 | 118 | 0.830 |
Why?
|
| Dementia | 3 | 2020 | 532 | 0.800 |
Why?
|
| Executive Function | 2 | 2015 | 98 | 0.780 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2022 | 53 | 0.760 |
Why?
|
| Aging | 9 | 2023 | 1429 | 0.760 |
Why?
|
| Prefrontal Cortex | 3 | 2023 | 145 | 0.730 |
Why?
|
| Exercise | 4 | 2023 | 422 | 0.720 |
Why?
|
| Iran | 17 | 2021 | 30 | 0.720 |
Why?
|
| Transcranial Magnetic Stimulation | 2 | 2021 | 16 | 0.710 |
Why?
|
| Health Status | 2 | 2021 | 209 | 0.710 |
Why?
|
| White Matter | 1 | 2021 | 123 | 0.690 |
Why?
|
| Mobility Limitation | 1 | 2021 | 91 | 0.690 |
Why?
|
| Longitudinal Studies | 11 | 2023 | 1300 | 0.670 |
Why?
|
| Child Development | 1 | 2020 | 67 | 0.670 |
Why?
|
| Cerebral Amyloid Angiopathy | 1 | 2021 | 108 | 0.670 |
Why?
|
| Mental Health | 1 | 2021 | 111 | 0.670 |
Why?
|
| Vision, Ocular | 1 | 2019 | 1 | 0.670 |
Why?
|
| Beta Rhythm | 1 | 2019 | 3 | 0.660 |
Why?
|
| Eyeglasses | 1 | 2019 | 4 | 0.660 |
Why?
|
| Agnosia | 1 | 2019 | 9 | 0.660 |
Why?
|
| Visual Perception | 1 | 2019 | 33 | 0.660 |
Why?
|
| Stroke Rehabilitation | 1 | 2019 | 19 | 0.650 |
Why?
|
| Blood Pressure | 2 | 2020 | 185 | 0.650 |
Why?
|
| Brain Infarction | 1 | 2020 | 71 | 0.650 |
Why?
|
| Cohort Studies | 13 | 2022 | 1781 | 0.640 |
Why?
|
| Motor Activity | 3 | 2019 | 304 | 0.640 |
Why?
|
| Cognition | 4 | 2023 | 1265 | 0.620 |
Why?
|
| Transcranial Direct Current Stimulation | 1 | 2017 | 9 | 0.570 |
Why?
|
| Upper Extremity | 1 | 2017 | 62 | 0.550 |
Why?
|
| Age Factors | 7 | 2021 | 716 | 0.540 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2015 | 27 | 0.510 |
Why?
|
| Middle Aged | 26 | 2023 | 8403 | 0.490 |
Why?
|
| Aspirin | 1 | 2015 | 74 | 0.480 |
Why?
|
| Triglycerides | 3 | 2022 | 57 | 0.470 |
Why?
|
| Cerebral Hemorrhage | 6 | 2023 | 104 | 0.460 |
Why?
|
| Case-Control Studies | 11 | 2023 | 532 | 0.430 |
Why?
|
| Metabolic Syndrome | 4 | 2018 | 60 | 0.430 |
Why?
|
| Receptors, Estrogen | 2 | 2023 | 56 | 0.420 |
Why?
|
| Autopsy | 3 | 2021 | 313 | 0.370 |
Why?
|
| Parkinson Disease | 3 | 2023 | 776 | 0.350 |
Why?
|
| Obesity | 4 | 2019 | 290 | 0.340 |
Why?
|
| Canada | 3 | 2015 | 48 | 0.330 |
Why?
|
| Prospective Studies | 9 | 2023 | 1633 | 0.330 |
Why?
|
| Time Factors | 4 | 2019 | 1336 | 0.320 |
Why?
|
| Follow-Up Studies | 8 | 2020 | 1689 | 0.320 |
Why?
|
| Adult | 17 | 2023 | 7336 | 0.310 |
Why?
|
| Waist Circumference | 4 | 2019 | 35 | 0.310 |
Why?
|
| Cognition Disorders | 2 | 2016 | 965 | 0.290 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2018 | 351 | 0.290 |
Why?
|
| Recovery of Function | 2 | 2019 | 255 | 0.280 |
Why?
|
| Disability Evaluation | 2 | 2019 | 252 | 0.270 |
Why?
|
| Proportional Hazards Models | 4 | 2020 | 332 | 0.250 |
Why?
|
| Neurofibrillary Tangles | 2 | 2023 | 182 | 0.240 |
Why?
|
| Hospitalization | 1 | 2007 | 292 | 0.240 |
Why?
|
| Waist-Hip Ratio | 5 | 2019 | 14 | 0.240 |
Why?
|
| Treatment Outcome | 5 | 2021 | 3231 | 0.230 |
Why?
|
| Risk Assessment | 4 | 2021 | 618 | 0.220 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2023 | 20 | 0.220 |
Why?
|
| Binge Drinking | 1 | 2023 | 10 | 0.210 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2023 | 21 | 0.210 |
Why?
|
| RNA | 1 | 2023 | 36 | 0.210 |
Why?
|
| Smoking | 3 | 2020 | 165 | 0.210 |
Why?
|
| Cerebrum | 1 | 2023 | 11 | 0.210 |
Why?
|
| Opium | 1 | 2022 | 1 | 0.210 |
Why?
|
| Cholesterol | 1 | 2022 | 59 | 0.200 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2023 | 54 | 0.200 |
Why?
|
| Spinal Cord | 1 | 2022 | 71 | 0.200 |
Why?
|
| Spastic Paraplegia, Hereditary | 1 | 2021 | 1 | 0.200 |
Why?
|
| Motor Cortex | 1 | 2021 | 17 | 0.190 |
Why?
|
| DNA-Binding Proteins | 1 | 2023 | 249 | 0.190 |
Why?
|
| Life Style | 2 | 2020 | 172 | 0.190 |
Why?
|
| Migraine Disorders | 1 | 2021 | 19 | 0.190 |
Why?
|
| Ontario | 1 | 2021 | 13 | 0.190 |
Why?
|
| Diabetes Mellitus | 2 | 2020 | 129 | 0.190 |
Why?
|
| Potassium | 1 | 2021 | 64 | 0.180 |
Why?
|
| Sodium | 1 | 2021 | 61 | 0.180 |
Why?
|
| Nerve Block | 1 | 2021 | 63 | 0.180 |
Why?
|
| Sex Factors | 2 | 2020 | 427 | 0.180 |
Why?
|
| Peptides | 1 | 2021 | 104 | 0.180 |
Why?
|
| Movement Disorders | 1 | 2021 | 82 | 0.170 |
Why?
|
| Biomarkers | 2 | 2020 | 554 | 0.170 |
Why?
|
| Psychomotor Performance | 1 | 2021 | 201 | 0.170 |
Why?
|
| Residence Characteristics | 2 | 2012 | 183 | 0.170 |
Why?
|
| Functional Laterality | 1 | 2019 | 65 | 0.160 |
Why?
|
| Depression | 1 | 2023 | 412 | 0.160 |
Why?
|
| Linear Models | 1 | 2020 | 231 | 0.160 |
Why?
|
| Apolipoproteins E | 1 | 2020 | 226 | 0.160 |
Why?
|
| Noncommunicable Diseases | 1 | 2018 | 2 | 0.160 |
Why?
|
| Heredity | 1 | 2018 | 7 | 0.160 |
Why?
|
| Pedigree | 1 | 2018 | 48 | 0.160 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 281 | 0.150 |
Why?
|
| Glycogen Storage Disease Type III | 1 | 2018 | 1 | 0.150 |
Why?
|
| Glycogen | 1 | 2018 | 16 | 0.150 |
Why?
|
| Pilot Projects | 1 | 2019 | 392 | 0.150 |
Why?
|
| Milk | 1 | 2017 | 14 | 0.150 |
Why?
|
| Nonlinear Dynamics | 1 | 2017 | 13 | 0.150 |
Why?
|
| CADASIL | 1 | 2017 | 1 | 0.140 |
Why?
|
| Menopause | 1 | 2018 | 92 | 0.140 |
Why?
|
| Genotype | 1 | 2018 | 326 | 0.140 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2018 | 107 | 0.140 |
Why?
|
| Research Design | 1 | 2018 | 188 | 0.140 |
Why?
|
| Chicago | 1 | 2020 | 869 | 0.140 |
Why?
|
| Feasibility Studies | 1 | 2017 | 207 | 0.140 |
Why?
|
| Amphetamine-Related Disorders | 1 | 2016 | 3 | 0.140 |
Why?
|
| Vasodilation | 1 | 2016 | 5 | 0.140 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2016 | 7 | 0.140 |
Why?
|
| Mutation | 1 | 2018 | 325 | 0.130 |
Why?
|
| Methamphetamine | 1 | 2016 | 22 | 0.130 |
Why?
|
| Central Nervous System Stimulants | 1 | 2016 | 37 | 0.130 |
Why?
|
| Child | 1 | 2020 | 1277 | 0.130 |
Why?
|
| Neuropathology | 1 | 2016 | 84 | 0.130 |
Why?
|
| Predictive Value of Tests | 2 | 2015 | 443 | 0.130 |
Why?
|
| Risk Reduction Behavior | 1 | 2016 | 39 | 0.130 |
Why?
|
| Blood Chemical Analysis | 1 | 2015 | 15 | 0.130 |
Why?
|
| Cholesterol, HDL | 1 | 2015 | 25 | 0.130 |
Why?
|
| Myocardial Ischemia | 1 | 2016 | 37 | 0.130 |
Why?
|
| Cross-Sectional Studies | 2 | 2016 | 847 | 0.120 |
Why?
|
| Prediabetic State | 1 | 2014 | 2 | 0.120 |
Why?
|
| ROC Curve | 3 | 2022 | 129 | 0.120 |
Why?
|
| Heart Rate | 1 | 2014 | 109 | 0.110 |
Why?
|
| Incidental Findings | 1 | 2014 | 13 | 0.110 |
Why?
|
| Body Mass Index | 3 | 2023 | 419 | 0.110 |
Why?
|
| Memory | 1 | 2015 | 296 | 0.110 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2014 | 177 | 0.100 |
Why?
|
| Rural Population | 1 | 2012 | 23 | 0.100 |
Why?
|
| Quality of Life | 1 | 2016 | 600 | 0.090 |
Why?
|
| Urban Population | 1 | 2012 | 149 | 0.090 |
Why?
|
| Phenotype | 2 | 2023 | 292 | 0.090 |
Why?
|
| Alcohol Drinking | 2 | 2022 | 72 | 0.080 |
Why?
|
| Logistic Models | 1 | 2010 | 366 | 0.080 |
Why?
|
| Efferent Pathways | 1 | 2008 | 1 | 0.080 |
Why?
|
| Neural Conduction | 1 | 2008 | 10 | 0.080 |
Why?
|
| Retrospective Studies | 2 | 2022 | 3220 | 0.070 |
Why?
|
| Action Potentials | 1 | 2008 | 87 | 0.070 |
Why?
|
| Skin | 1 | 2008 | 99 | 0.070 |
Why?
|
| Age Distribution | 1 | 2007 | 84 | 0.070 |
Why?
|
| Comorbidity | 2 | 2021 | 457 | 0.070 |
Why?
|
| Middle East | 2 | 2017 | 5 | 0.070 |
Why?
|
| Developing Countries | 2 | 2018 | 13 | 0.070 |
Why?
|
| Diabetes Complications | 2 | 2017 | 57 | 0.070 |
Why?
|
| Evidence-Based Medicine | 2 | 2018 | 170 | 0.070 |
Why?
|
| Odds Ratio | 2 | 2017 | 244 | 0.070 |
Why?
|
| Europe | 2 | 2016 | 64 | 0.060 |
Why?
|
| Prognosis | 2 | 2018 | 739 | 0.060 |
Why?
|
| Angina, Unstable | 2 | 2014 | 10 | 0.060 |
Why?
|
| Death, Sudden, Cardiac | 2 | 2014 | 10 | 0.060 |
Why?
|
| Prevalence | 2 | 2016 | 435 | 0.060 |
Why?
|
| Surveys and Questionnaires | 2 | 2019 | 1077 | 0.050 |
Why?
|
| Infarction | 1 | 2023 | 30 | 0.050 |
Why?
|
| Adaptor Protein Complex 1 | 1 | 2023 | 7 | 0.050 |
Why?
|
| Adaptor Protein Complex beta Subunits | 1 | 2023 | 7 | 0.050 |
Why?
|
| Olfactory Bulb | 1 | 2023 | 16 | 0.050 |
Why?
|
| Proteome | 1 | 2023 | 38 | 0.050 |
Why?
|
| Myocardial Infarction | 2 | 2014 | 129 | 0.050 |
Why?
|
| Health Surveys | 2 | 2013 | 85 | 0.050 |
Why?
|
| Lewy Bodies | 1 | 2023 | 171 | 0.050 |
Why?
|
| Muscle Spasticity | 1 | 2021 | 4 | 0.050 |
Why?
|
| Triamcinolone | 1 | 2021 | 4 | 0.050 |
Why?
|
| Lidocaine | 1 | 2021 | 21 | 0.050 |
Why?
|
| Headache | 1 | 2021 | 32 | 0.050 |
Why?
|
| Lower Extremity | 1 | 2021 | 39 | 0.050 |
Why?
|
| Potassium, Dietary | 1 | 2021 | 1 | 0.050 |
Why?
|
| Reactive Oxygen Species | 1 | 2022 | 103 | 0.050 |
Why?
|
| Young Adult | 2 | 2018 | 1855 | 0.050 |
Why?
|
| Sodium, Dietary | 1 | 2021 | 6 | 0.050 |
Why?
|
| Causality | 1 | 2021 | 55 | 0.050 |
Why?
|
| Glomerular Filtration Rate | 1 | 2021 | 47 | 0.050 |
Why?
|
| Stress, Psychological | 1 | 2022 | 211 | 0.040 |
Why?
|
| Analysis of Variance | 1 | 2021 | 256 | 0.040 |
Why?
|
| Sleep | 1 | 2023 | 316 | 0.040 |
Why?
|
| Blood Pressure Determination | 1 | 2019 | 12 | 0.040 |
Why?
|
| Waist-Height Ratio | 1 | 2019 | 6 | 0.040 |
Why?
|
| Likelihood Functions | 1 | 2019 | 27 | 0.040 |
Why?
|
| Activities of Daily Living | 1 | 2023 | 560 | 0.040 |
Why?
|
| Anthropometry | 1 | 2019 | 36 | 0.040 |
Why?
|
| Adiposity | 1 | 2019 | 32 | 0.040 |
Why?
|
| Interviews as Topic | 1 | 2019 | 111 | 0.040 |
Why?
|
| Gene-Environment Interaction | 1 | 2018 | 18 | 0.040 |
Why?
|
| Physical Examination | 1 | 2019 | 110 | 0.040 |
Why?
|
| Glycogen Debranching Enzyme System | 1 | 2018 | 1 | 0.040 |
Why?
|
| Developed Countries | 1 | 2018 | 2 | 0.040 |
Why?
|
| Epigenesis, Genetic | 1 | 2018 | 75 | 0.040 |
Why?
|
| Mediterranean Region | 1 | 2017 | 3 | 0.040 |
Why?
|
| Patient Outcome Assessment | 1 | 2018 | 39 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2018 | 246 | 0.040 |
Why?
|
| Age of Onset | 1 | 2018 | 95 | 0.040 |
Why?
|
| Poverty | 1 | 2018 | 92 | 0.040 |
Why?
|
| Microvessels | 1 | 2017 | 14 | 0.040 |
Why?
|
| Health Services Accessibility | 1 | 2018 | 98 | 0.040 |
Why?
|
| Liver Transplantation | 1 | 2018 | 93 | 0.030 |
Why?
|
| Nitroglycerin | 1 | 2016 | 1 | 0.030 |
Why?
|
| Carotid Artery, Common | 1 | 2016 | 3 | 0.030 |
Why?
|
| Overweight | 1 | 2017 | 74 | 0.030 |
Why?
|
| Carotid Intima-Media Thickness | 1 | 2016 | 17 | 0.030 |
Why?
|
| Apolipoproteins B | 1 | 2016 | 2 | 0.030 |
Why?
|
| Apolipoprotein A-I | 1 | 2016 | 2 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2017 | 255 | 0.030 |
Why?
|
| Asia | 1 | 2016 | 10 | 0.030 |
Why?
|
| Africa | 1 | 2016 | 11 | 0.030 |
Why?
|
| Vasodilator Agents | 1 | 2016 | 26 | 0.030 |
Why?
|
| Australia | 1 | 2016 | 37 | 0.030 |
Why?
|
| International Cooperation | 1 | 2016 | 22 | 0.030 |
Why?
|
| Obesity, Abdominal | 1 | 2016 | 15 | 0.030 |
Why?
|
| China | 1 | 2016 | 46 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 299 | 0.030 |
Why?
|
| Risk | 1 | 2016 | 190 | 0.030 |
Why?
|
| Demography | 1 | 2016 | 66 | 0.030 |
Why?
|
| Reference Standards | 1 | 2015 | 24 | 0.030 |
Why?
|
| Feeding Behavior | 1 | 2016 | 87 | 0.030 |
Why?
|
| Health Status Disparities | 1 | 2016 | 65 | 0.030 |
Why?
|
| Health Behavior | 1 | 2016 | 136 | 0.030 |
Why?
|
| Self Report | 1 | 2016 | 204 | 0.030 |
Why?
|
| United States | 1 | 2021 | 1943 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2016 | 277 | 0.030 |
Why?
|
| Muscle, Skeletal | 1 | 2018 | 383 | 0.030 |
Why?
|
| Atrial Fibrillation | 1 | 2016 | 120 | 0.030 |
Why?
|
| Rural Health | 1 | 2013 | 6 | 0.030 |
Why?
|
| Diet | 1 | 2014 | 207 | 0.030 |
Why?
|
| Urban Health | 1 | 2013 | 21 | 0.030 |
Why?
|
| Adolescent | 1 | 2018 | 2076 | 0.030 |
Why?
|
| Hyperlipidemias | 1 | 2012 | 13 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2012 | 85 | 0.020 |
Why?
|
| Public Health | 1 | 2012 | 66 | 0.020 |
Why?
|
| Reference Values | 1 | 2012 | 183 | 0.020 |
Why?
|
| Survival Rate | 1 | 2012 | 308 | 0.020 |
Why?
|
| Animals | 1 | 2017 | 3510 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2012 | 913 | 0.020 |
Why?
|
| Electric Stimulation | 1 | 2008 | 46 | 0.020 |
Why?
|
| Electrophysiology | 1 | 2008 | 97 | 0.020 |
Why?
|
| Hand | 1 | 2008 | 32 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2008 | 235 | 0.020 |
Why?
|